Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANCN NASDAQ:CAPR NASDAQ:XTLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$1.71+1.8%$21.77$0.51▼$10.55$12.69M0.933.15 million shs30,960 shsCAPRCapricor Therapeutics$28.87-2.4%$31.68$4.30▼$40.37$1.67B0.481.16 million shs569,738 shsXTLBXTL Biopharmaceuticals$2.51+0.8%$2.59$2.12▼$10.28$5.53M1.645.93 million shs37,493 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics0.00%0.00%0.00%+8.92%+23.02%CAPRCapricor Therapeutics0.00%+0.28%-14.74%+1.26%+159.62%XTLBXTL Biopharmaceuticals0.00%-3.83%-1.84%-26.35%-85.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$1.71+1.8%$21.77$0.51▼$10.55$12.69M0.933.15 million shs30,960 shsCAPRCapricor Therapeutics$28.87-2.4%$31.68$4.30▼$40.37$1.67B0.481.16 million shs569,738 shsXTLBXTL Biopharmaceuticals$2.51+0.8%$2.59$2.12▼$10.28$5.53M1.645.93 million shs37,493 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics0.00%0.00%0.00%+8.92%+23.02%CAPRCapricor Therapeutics0.00%+0.28%-14.74%+1.26%+159.62%XTLBXTL Biopharmaceuticals0.00%-3.83%-1.84%-26.35%-85.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANCNAnchiano Therapeutics 0.00N/AN/AN/ACAPRCapricor Therapeutics 2.80Moderate Buy$48.3667.52% UpsideXTLBXTL Biopharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest XTLB, ANCN, and CAPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CAPRCapricor Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/13/2026CAPRCapricor Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.004/2/2026XTLBXTL Biopharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026CAPRCapricor Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$62.003/13/2026CAPRCapricor Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $63.003/13/2026CAPRCapricor Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$45.00 ➝ $58.003/10/2026CAPRCapricor Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/ACAPRCapricor Therapeutics$22.27M75.07N/AN/A$4.81 per share6.00XTLBXTL Biopharmaceuticals$968K5.71N/AN/A$2.47 per share1.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANCNAnchiano Therapeutics-$27.12M-$3.4611.40N/AN/AN/A36.08%27.40%N/ACAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)XTLBXTL Biopharmaceuticals-$1.03M-$0.64N/AN/AN/AN/AN/AN/AN/ALatest XTLB, ANCN, and CAPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A3/12/2026Q4 2025CAPRCapricor Therapeutics-$0.51-$0.62-$0.11-$0.62$0.53 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANCNAnchiano TherapeuticsN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANCNAnchiano TherapeuticsN/A3.253.25CAPRCapricor TherapeuticsN/A8.428.42XTLBXTL BiopharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANCNAnchiano Therapeutics9.05%CAPRCapricor Therapeutics21.68%XTLBXTL Biopharmaceuticals4.40%Insider OwnershipCompanyInsider OwnershipANCNAnchiano Therapeutics6.88%CAPRCapricor Therapeutics9.20%XTLBXTL Biopharmaceuticals29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableXTLBXTL BiopharmaceuticalsN/A2.20 million1.57 millionNot OptionableXTLB, ANCN, and CAPR HeadlinesRecent News About These CompaniesXTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from NasdaqMay 23 at 2:40 PM | finanznachrichten.deXTL Announces Receipt of Staff Delist Determination from NasdaqMay 22 at 4:10 PM | globenewswire.comXTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital RaiseMay 15, 2026 | tipranks.comXTL Biopharmaceuticals Ltd ADR XTLBMay 14, 2026 | morningstar.comMXTL Biopharmaceuticals Delays 20-F Amid Subsidiary LiquidationMay 3, 2026 | theglobeandmail.comXTL Biopharmaceuticals Ltd.May 1, 2026 | marketwatch.comWashington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a KeyMay 1, 2026 | theglobeandmail.comXTLB stock surges 50%, breaches 200-DMA for first time in over 3 months – here’s what the acquisition of Psyga Bio brings to the tableMay 1, 2026 | msn.comXTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and ...April 29, 2026 | markets.businessinsider.comXTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growthApril 29, 2026 | msn.comXTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcementApril 29, 2026 | quiverquant.comQXTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug PipelineApril 29, 2026 | tipranks.comXTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin TechnologiesApril 29, 2026 | globenewswire.comXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Announces ADS Ratio ChangeMarch 21, 2026 | finanznachrichten.deXTL Biopharmaceuticals Announces ADS Ratio ChangeMarch 20, 2026 | globenewswire.comXTL Biopharmaceuticals Ends Acquisition Talks After NeuroNOS LOI ExpiresMarch 10, 2026 | tipranks.comXTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request HearingFebruary 28, 2026 | finanznachrichten.deXTL Biopharmaceuticals stock falls on Nasdaq delisting noticeFebruary 27, 2026 | investing.comXTL Biopharmaceuticals Limited Faces Nasdaq Delisting Following Insolvency of Subsidiary The Social ProxyFebruary 27, 2026 | quiverquant.comQXTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request HearingFebruary 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTLB, ANCN, and CAPR Company DescriptionsAnchiano Therapeutics NASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Capricor Therapeutics NASDAQ:CAPR$28.87 -0.71 (-2.40%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.61 -0.26 (-0.90%) As of 05/22/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. XTL Biopharmaceuticals NASDAQ:XTLB$2.51 +0.02 (+0.80%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.30 -0.21 (-8.21%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
